Tenaya Therapeutics, Inc. (TNYA) Dividend History

Tenaya Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious, life-threatening genetic diseases, particularly those affecting the heart. Founded with the aim of transforming the treatment landscape, Tenaya leverages advanced genetics, stem cell biology, and disease modeling to identify and develop innovative medicines. The company's approach centers on understanding the underlying mechanisms of genetic disorders and translating this knowledge into targeted therapies to improve patient outcomes.

171 Oyster Point Blvd., Suite 500, South San Francisco, CA, 94080
Phone: 415-865-2066
Website: https://www.tenayatherapeutics.com

Dividend History

Tenaya Therapeutics, Inc. currently does not pay dividends

Company News

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

GlobeNewswire Inc.

Featured Companies: ADVM BIIB FDMT JNJ MGTX PASG RARE RCKT RGNX SRPT
Tenaya Therapeutics Announces Research Leadership Updates

Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role

GlobeNewswire Inc.
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET.

GlobeNewswire Inc.
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024

GlobeNewswire Inc.
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 14:40:23 UTC